Xencor (NASDAQ:XNCR) Hits New 52-Week High - Should You Buy?

Key Points

• Xencor shares reached a new 52-week high, trading as high as $39.85 after a prior close of $38.59.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and a $42.22 average price target, though ratings include one sell and three holds.
• Xencor reported quarterly EPS of $0.50, beating the consensus estimate of a $0.33 loss, while revenue of $116.52 million exceeded estimates and rose 453.3% year over year.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price hit a new 52-week high on Tuesday. The company traded as high as $39.85 and last traded at $39.66, with a volume of 42,047 shares trading hands. The stock had previously closed at $38.59.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wedbush boosted their price target on shares of Xencor from $30.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 27th. Truist Financial upped their target price on Xencor from $29.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, October 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a report on Monday, September 21st. Wall Street Zen upgraded shares of Xencor from a "hold" rating to a "buy" rating in a report on Saturday. Finally, JPMorgan Chase & Co. increased their target price on Xencor from $14.00 to $21.00 and gave the stock a "neutral" rating in a research note on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.22.

Xencor Price Performance

The stock has a 50 day simple moving average of $26.42 and a two-hundred day simple moving average of $17.59. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -24.77 and a beta of 0.78.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.83. The company had revenue of $116.52 million for the quarter, compared to analyst estimates of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.37%. The firm's revenue was up 453.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.08) earnings per share. Equities research analysts predict that Xencor, Inc. will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Xencor

Several large investors have recently modified their holdings of XNCR. Johnson & Johnson acquired a new stake in Xencor during the 2nd quarter worth approximately $12,043,798. Hsbc Holdings PLC increased its holdings in shares of Xencor by 114.2% in the 2nd quarter. Hsbc Holdings PLC now owns 125,482 shares of the biopharmaceutical company's stock valued at $2,083,000 after purchasing an additional 66,903 shares in the last quarter. Man Group plc acquired a new stake in shares of Xencor during the 2nd quarter valued at approximately $940,000. Primecap Management Co. CA acquired a new position in Xencor during the second quarter worth $163,919,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Xencor in the 2nd quarter worth about $7,828,524,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company's XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.